Needle Free Drug Delivery Devices Market

1. Orion Market Research Needle Free Drug Delivery Devices Market Size, Share, Growth, Industry Analysis Report and Forecast to 2025 Request a free sample of our report on Needle Free Drug Delivery Devices Market: https://www.omrglobal.com/request-sample/needle-free-drug-delivery-devices-market-size ------------------------------------------------------------------------------------ Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 7803040404

2. The Global Needle-Free Drug Delivery Devices Market is expected to exhibit remarkable growth during the forecast period. The market for drug delivery devices is expanding continuously as inventors find new approaches to deliver biologics and, cell and gene therapies. The conventional method of delivering drugs to the body includes tablets, syrups and most commonly injections; however, tablets and syrups work slowly and can cause some side effects to the patients. In addition, patients don’t wish to take medications through oral route due to bitter taste of the medications. And injection is painful due to piercing of needle into the body that can even cause mortality if it is not injected properly or if same needle is used repeatedly. Get Sample Copy of Needle Free Drug Delivery Devices Market at: https://www.omrglobal.com/request-sample/needle-free-drug-delivery-devices-market-size Some of the key players operating in the market include Antares Pharma, Inc., 3M Co., Valeritas Inc., Endo International PLC, Injex Pharma AG, Pharmajet Inc., Inovio Pharmaceuticals, Inc., and Penjet Corp. Needlestick injury is also possible if a broken needle is left in the body, and it can cause infections and transmit diseases to human body. Keeping in mind these limitations of the conventional method of drug delivery, technologies have been advanced in the needle-free drug delivery devices industry in order to deliver drugs to patients with no pain. One of the advancements is the needle-free auto and pen injectors that are designed to deliver a single dose of a specific drug. Autoinjectors are easy to use and offer self-administration to the patients. These were designed to combat the hesitation regarding self-administration of needle-based medications. Advancement in auto-injector design helping pharmaceutical companies to market their drugs more effectively by helping patients to comply with their dosage prescriptions. Further, the players operating in the global needle-free drug delivery devices market are establishing collaborations to bring new devices into the market. For instance, In July 2018, Pharma Jet and Mundipharma signed an agreement for marketing and distributing Tropis and Stratis needle-free drug-delivery devices of Pharma Jet to more than 120 markets across the globe. The devices are designed for vaccine immunizations. This partnership focuses on providing access to this needle-free technology, to more patients, especially in the emerging economies where outbreaks typically occur. For More Information, get A full report of Needle Free Drug Delivery Devices Market is available at:https://www.omrglobal.com/industry-reports/needle-free-drug-delivery- devices-market-size Pharma Jet’s portfolio consists of: Stratis IM/SC (Stratis) for intramuscular or subcutaneous delivery Tropis ID (Tropis) for intradermal delivery of liquid medicines directly into the skin

3. Further, in October 2017, Takeda Pharmaceutical Co. Ltd. and Portal Instruments established a collaboration for the development and commercialization of Portal’s needle-free drug delivery device for potential use with Takeda’s investigational or approved biologic medicines. The Portal device is potentially used for applications across a wide range of biologic medicines that currently require administration through an injection. Takeda in its first development program for potentially using this device would be for investigational use with Entyvio (vedolizumab). Entyvio is a monoclonal antibody used for adults living with moderately to severely active ulcerative colitis or Crohn’s disease. This antibody is currently administered through intravenous infusion. A Phase III clinical trial program is currently being in operation to evaluate the efficacy and safety of a subcutaneous formulation of vedolizumab in adults living with moderately to severely active ulcerative colitis or Crohn’s disease. Needle-Free Drug Delivery Devices Market Segmentation By Technology •Inhaler Technology •Jet Injectors •Transdermal Patch Technology •Others Needle-free Technology By Application •Pain Management •Insulin delivery for Diabetes •Vaccines Delivery •Pediatric Injections •Others Applications Needle-Free Drug Delivery Devices Market – Segment by Region North America •United States •Canada Europe •Germany •United Kingdom •France

4. •Spain •Italy •Rest of Europe Asia-Pacific •China •Japan •India •Rest of Asia-Pacific Rest of the World •Latin America •Middle East and Africa For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/needle-free-drug-delivery-devices- market-size About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. For More Information, Visit https://www.omrglobal.com/ Media Contact: Company Name: Orion Market Research

5. Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 7803040404